BenevolentAI’s drug discovery platform identifies novel target for ulcerative colitis

London-based AI pioneer BenevolentAI has identified a novel target for ulcerative colitis through its drug discovery platform.

The candidate was identified by scientists who used BenevolentAI’s target ID tools and machine learning models to identify and experimentally validate a novel biological target. Impressively, the achievement was made without any prior reference in published alliteration or patents linking the gene to ulcerative colitis.

Anne Phelan, Chief...